ArticleThe Laryngoscope2025
Allergic Rhinitis-Underrepresented Populations and Barriers to Healthcare Access.
Article in The Laryngoscope, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Allergic Rhinitis-Underrepresented Populations and Barriers to Healthcare Access.The Laryngoscope · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo establish the prevalence of allergic rhinitis (AR), categorized by demographics and barriers to healthcare, and the prevalence of antihistamine and nasal steroid use in these subgroups.
methodsWe performed a retrospective, cross-sectional study utilizing the All of Us Database. Sociodemographic factors among AR patients were compared via Chi-Square analysis and multivariable logistic regression (MLR). Subgroups of AR patients with or without nasal steroid spray or oral antihistamine listed in the electronic health record (EHR) were compared via chi-square analysis and MLR.
results47,224 participants were identified with AR, an 11.6% estimated prevalence. AR patients were more commonly White (12.8% vs. 10.6%, p < 0.001), female (13.1% vs. 9.1%, p < 0.001), and older than 65 (14.7% vs. 7.6% vs. 11.6%, p < 0.001). MLR identified older age (OR 1.018, CI: 1.017-1.018), income > $35,000 (OR 1.035, CI: 1.021-1.049), finishing high school/college (OR 1.140, CI: 1.113-1.167; OR 1.113, CI: 1.085, 1.142), and health insurance coverage (OR 2.003, CI: 1.924-2.087) as predictive factors for AR. Patients with nasal steroid spray and/or oral antihistamine listed in the EHR were more commonly Black (OR 1.250, CI: 1.177-1.328; OR 1.491, CI: 1.398-1.590) and had an income < $35,000 (OR 0.856, CI: 0.814-0.900; OR 0.724, CI: 0.687-0.764).
conclusionAR patients were more likely to be insured, while oral antihistamines/nasal steroid spray listed in the EHR were associated with lower income and Black race. These results highlight the barriers to AR diagnoses and treatment and the need for providers to ensure that underserved patients are offered appropriate care. LEVEL OF EVIDENCE: 3:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.